Dosimetry for radiopharmaceutical therapy: From measurement to dose justification
Why dosimetry for radiopharmaceutical therapy needs more than absorbed dose. How BED, radiation dosimetry &…
Hunter Stephens, PhD2026 年 7 月 7 日
Enhancing clinical trials with real-world evidence in pregnancy research
Learn how real-world evidence improves clinical trials in pregnancy by enhancing safety data, trial design,…
Certara2026 年 6 月 26 日
Mechanistic Modelling of CRS in T-cell Engagers – An Application for Blinatumomab
Discover how Quantitative Systems Pharmacology (QSP) was used to predict cytokine release syndrome risk and…
Certara2026 年 6 月 23 日
Certara Integrates D360™ with Secondary Intelligence™ Software to Enhance Predicting Drug Safety Risk
Certara integrates D360 with Secondary Intelligence to help drug researchers identify off-target safety risks earlier…
Certara2026 年 6 月 12 日
BioSpace webinar: Streamlining Nonclinical Development with FDA NAMs
Learn how to apply FDA NAM guidance to streamline nonclinical development, support IND decisions, and…
Certara2026 年 5 月 8 日
Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome
Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome
A newly approved RNA interference (RNAi) therapy lowers harmful triglyceride (TG) levels in patients with…
Certara2026 年 5 月 7 日
Population Pharmacokinetics and Exposure-Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation
This study evaluated how the leukemia drug ziftomenib behaves in the body and whether different…
Certara2026 年 5 月 7 日
Population Pharmacokinetic Modeling and Exposure-Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies
Population pharmacokinetic (PopPK) and exposure-response modeling were used to support the clinical development of nemtabrutinib,…
Certara2026 年 5 月 7 日
